



澳門特別行政區政府
Governo da Região Administrativa Especial de Macau
衛生局
Serviços de Saúde

No.1

參照編號 0768/DAF/10

日期: 19/07/2010

Nº ref.

Data/Date:

由

De/From: 部門/Dept.: 藥物事務廳 Department of Pharmaceutical Affairs

簽署者/Ass./Signat.: 蔡炳祥廳長 Dr. Choi Peng Cheong – Department Chief

傳真機/Fax: (853)-28524016

致: 醫生、藥劑師及其他衛生專業人士

Para/To: Physicians, pharmacists and other healthcare professionals

主題: 關於pregabalin(Lyrica®)安全性的最新資訊

Ass./Subject: Latest safety update on pregabalin(Lyrica®)

頁數: 1/2

Nº folhas/N.pages:

隨件附上一則關於pregabalin(Lyrica®)安全性的最新資訊, 請醫生、藥劑師及其他衛生專業人士參閱, 如台端懷疑由上述或其他藥物引致的任何不良反應, 請以下列任一方式向本廳通報:

- 網上通報 - http://www.ssm.gov.mo/design/webservices/c_wservices_main.htm
- 郵寄 - 澳門土多烏拜斯大馬路 51號 華仁中心二樓
- 傳真 - 28524016

通報人士可親臨藥物事務廳索取或在http://www.ssm.gov.mo/design/services/serpt_chn.pdf網址上下載通報表格。如有任何疑問, 請於辦公時間致電85983517或85983439與藥物監測暨管理處楊燕雯藥劑師或林俊耀藥劑師聯絡, 倘遇緊急的情況, 亦可於非辦公時間傳呼85008068。

謹祝 台安!

Attached herewith is the latest safety update on pregabalin(Lyrica®) for your reference. If physicians, pharmacists or other healthcare professionals suspect any kind of adverse reaction subsequent to the use of the above or any other medication, please report through any of the following methods:

- Online - http://www.ssm.gov.mo/design/webservices/c_wservices_main.htm
- Mail to - 51 Avenida do Sidonio Pais, Edificio China Plaza, 2nd Floor, Macao S.A.R., China
- Fax to - 853-28524016

The report form can be collected in person at Department of Pharmaceutical Affairs or downloaded from the website designated as http://www.ssm.gov.mo/design/services/serpt_chn.pdf. Should you have any query, please contact Ms. Beatrice Young or Mr. Jeffrey Lam at 8598-3517 or 8598-3439 respectively from the Division of Pharmacovigilance and Pharmacoeconomics during office hours. In case of urgent situations during off hours, please page 85008068.

Thanking you in advance for your attention!

藥物事務廳廳長
Chief, Department of Pharmaceutical Affairs

Deen

蔡炳祥
Choi Peng Cheong



澳門特別行政區政府
Governo da Região Administrativa Especial de Macau
衛生局
Serviços de Saúde

主題：關於pregabalin(Lyrica[®])安全性的最新資訊
Subject：Latest safety update on pregabalin(Lyrica[®])

由於服用抗癲癇藥物的病人可能增加自毀傾向（自殺行為和意念）的風險，本處於2008年曾向醫生、藥劑師及其他衛生專業人士發出相關的安全性通告。加拿大衛生部近期亦表示於2005年7月至2009年12月期間，接獲16宗懷疑病人使用pregabalin(Lyrica[®])後產生自殺意念的個案，以及1宗出現自殺行為的報告。

雖然上述因果關係尚未確立，基於以上事實，對所有正服用或剛開始服用pregabalin(Lyrica[®])的病人，醫生、藥劑師及其他衛生專業人士都應密切監測病人在行為上有否出現顯著變化，從而了解他們有否產生自殺念頭或行為、其自殺念頭或行為有否惡化或有否患上抑鬱症。另外，衛生專業人士亦須通知病人、其家人及照護者留意有關該藥可能增加病人自毀傾向的潛在風險，以便他們及早察覺病人在行為上出現任何不尋常的轉變，以及能立即通知醫生。

藥物監測暨管理處

Due to an increased risk of suicidality (suicidal behaviour and ideation) in patients taking anti-epileptic medicines, DFF issued a safety alert to physicians, pharmacists and other healthcare professionals in 2008. Recent release from Health Canada said that from July 2005 to December 2009, it received 16 reports of suicidal ideation and 1 report of suicide attempt suspected of being associated with the use of pregabalin(Lyrica[®]).

Although the causal relationship is not established, in light of the above, physicians, pharmacists or other healthcare professionals should closely monitor all patients currently taking or starting on Lyrica[®] for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression. Besides, they should also inform patients, their families, and caregivers of the potential for an increase in the risk of suicidality so they are aware and able to immediately notify their doctor of any unusual behavioral changes.

Division of Pharmacovigilance
and Pharmacoeconomics(DFF)

參考資料/Reference and website：

http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v20n3-eng.php

http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/bulletin/carn-bcei_v20n3-eng.pdf